Pelubiprofen: A Comprehensive Pharmacological and Clinical Monograph

1.0 Executive Summary

Pelubiprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid class, structurally analogous to ibuprofen, developed by the South Korean firm Daewon Pharmaceutical.[1] It is characterized by a dual mechanism of action that distinguishes it from many other agents in its class. The primary mechanism involves the inhibition of cyclooxygenase (COX) enzymes, with a moderate preference for the inducible COX-2 isoform over the constitutive COX-1 isoform.[3] This is complemented by a distinct secondary mechanism: the suppression of the pro-inflammatory TAK1-IKK-NF-κB signaling pathway, which downregulates the expression of multiple inflammatory genes, including COX-2 itself.[3]

Clinically, Pelubiprofen is approved for the symptomatic relief of osteoarthritis, rheumatoid arthritis, and low back pain in several countries, including South Korea and Russia.[1] It has also been investigated in Phase III clinical trials for additional indications such as the management of fever associated with acute upper respiratory tract infections (URTIs) and post-traumatic pain.[6] Pivotal clinical trials have established its efficacy as non-inferior to active comparators, including the highly selective COX-2 inhibitor celecoxib for rheumatoid arthritis, the moderately selective NSAID aceclofenac for osteoarthritis, and loxoprofen for fever.[4]

The safety and tolerability profile of Pelubiprofen is complex and reflects its pharmacology. It carries the class-wide cardiovascular and renal risks associated with all NSAIDs. While developed as a prodrug with COX-2 preference to improve gastrointestinal (GI) tolerability, its safety profile relative to other NSAIDs is nuanced. Clinical evidence indicates a less favorable GI safety profile compared to celecoxib but a potentially improved profile, particularly in its controlled-release (CR) formulation, when compared to aceclofenac.[4]

Significant research and development have focused on optimizing Pelubiprofen's pharmacokinetic profile and improving its tolerability through advanced formulations. The development of controlled-release tablets and a more soluble tromethamine salt have been key strategies to enhance absorption, provide more convenient dosing regimens, and mitigate adverse events.[1] These formulation advancements are critical to understanding its clinical performance.

In conclusion, Pelubiprofen is a potent anti-inflammatory and analgesic agent with a unique dual mechanism of action. It offers efficacy comparable to that of established NSAIDs for several common inflammatory conditions. Its place in therapy is defined by this efficacy, balanced against a distinct benefit-risk profile that requires careful clinical consideration, particularly regarding patient-specific gastrointestinal and cardiovascular risk factors and the specific formulation being administered.

2.0 Chemical Identity and Physicochemical Properties

A comprehensive understanding of Pelubiprofen's pharmacological and pharmacokinetic behavior begins with a precise characterization of its chemical and physical properties. This section details its nomenclature, structural features, and key physicochemical parameters that govern its activity and formulation.

2.1 Nomenclature and Standardized Identifiers

To ensure unambiguous identification across scientific literature, regulatory filings, and chemical databases, Pelubiprofen is cataloged under several standardized names and identifiers.

• Generic Name: Pelubiprofen.[12]
• International Nonproprietary Name (INN): The designated INN is pelubiprofen. Corresponding names in other languages include Pélubiprofène (French), Pelubiprofeno (Spanish), and Pelubiprofenum (Latin).[13]
• Systematic (IUPAC) Name: The formal IUPAC name for the compound is 2-[(E)-(2-Oxocyclohexylidene)methyl]phenyl]propanoic acid.[1]
• Synonyms and Development Codes: Throughout its development and in various research contexts, Pelubiprofen has been referred to by several codes and synonyms. These include RS-2131, CS-670, DW-330, DW-330SR, and 2-OCMPP.[15]
• Database Identifiers: Key identifiers from major international databases are consolidated in Table 1, facilitating cross-referencing and further research.

Table 1: Chemical and Physical Identifiers of Pelubiprofen

Identifier Type	Value	Source Snippet(s)
DrugBank ID	DB12150	1
CAS Number	69956-77-0	1
PubChem CID	5282203	1
UNII	1619C79FVJ	1
ChEMBL ID	CHEMBL69308	15
ATC Code	M01AE20	1
KEGG ID	D01865	15

This centralization of identifiers is fundamental for a technical monograph, allowing professionals to accurately locate Pelubiprofen across diverse platforms, from regulatory agencies to clinical trial registries, thereby ensuring precision in research and clinical communication.

2.2 Chemical Structure, Formula, and Stereochemistry

Pelubiprofen's structure defines its membership in the "profen" family of NSAIDs and dictates its biological activity.

• Chemical Class: Pelubiprofen is classified as a phenylpropanoic acid, belonging to the broader category of aryl propionic acid derivatives. This structural classification places it in the same family as ibuprofen and naproxen.[12]
• Molecular Formula: The empirical chemical formula for Pelubiprofen is C16​H18​O3​.[1]
• Structural Representation: The molecule's two-dimensional structure is unambiguously defined by the following standard notations:
• SMILES: CC(C1=CC=C(C=C1)/C=C/2\CCCCC2=O)C(=O)O.[1]
• InChI: InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+.[1]
• InChIKey: AUZUGWXLBGZUPP-GXDHUFHOSA-N.[1]
• Stereochemistry: A critical structural feature of Pelubiprofen is that the marketed, INN-defined agent is a racemic mixture of its R- and S-enantiomers.[17] Like many profens, the propionic acid side chain creates a chiral center. The administration of a racemic mixture is significant, as often one enantiomer (typically the S-form for profens) is responsible for the majority of the therapeutic activity, while the other may be inactive, less active, or contribute differently to the side effect profile. This characteristic places Pelubiprofen in the context of older profens like ibuprofen, which are also administered as racemates, and raises questions about whether chiral inversion occurs in vivo or if a single-enantiomer formulation could offer an improved therapeutic index in the future.

2.3 Physicochemical Characteristics

The physical properties of Pelubiprofen are crucial determinants of its absorption, distribution, formulation, and overall drug-like behavior.

• Molar Mass / Molecular Weight: The calculated molecular weight is approximately 258.32 g·mol⁻¹.[1]
• Appearance: In its solid state, Pelubiprofen is described as a white to off-white powder.[20]
• Solubility: Pelubiprofen exhibits very low aqueous solubility, with a reported value of 0.0147 mg/mL.[12] This property presents a significant challenge for oral bioavailability. The poor water solubility is not merely a chemical statistic but a central factor that has driven substantial post-approval research and development by its manufacturer. The challenge of ensuring consistent and adequate absorption from a poorly soluble compound directly led to the strategic development of alternative formulations, most notably the pelubiprofen tromethamine salt, which was specifically designed to enhance solubility and improve absorption characteristics.[1] In contrast to its poor aqueous solubility, it is highly soluble in organic solvents like dimethyl sulfoxide (DMSO), with reported solubilities of 80-100 mg/mL, a relevant parameter for conducting in vitro experiments.[20]
• Acidity (pKa): As a carboxylic acid derivative, Pelubiprofen is a weak acid. Its strongest acidic pKa is reported to be 4.11, consistent with the carboxyl group on the propionic acid moiety.[12]
• Lipophilicity (LogP): The partition coefficient (LogP) values range from 2.37 to 3.72 across different computational models, indicating moderate lipophilicity.[19] This property is favorable for traversing biological membranes and supports its suitability for oral administration.
• Drug-likeness: Pelubiprofen adheres to Lipinski's Rule of Five, with zero violations reported.[17] This computational assessment suggests that the molecule possesses favorable physicochemical properties (e.g., appropriate molecular weight, lipophilicity, and hydrogen bond donor/acceptor counts) that are generally associated with good oral bioavailability and drug-like characteristics.

3.0 Pharmacology

Pelubiprofen exerts its therapeutic effects through a sophisticated, dual-pronged mechanism of action that involves both direct enzymatic inhibition and modulation of intracellular signaling pathways central to the inflammatory response. This combination of activities defines its unique pharmacological profile within the NSAID class.

3.1 Primary Mechanism of Action: Cyclooxygenase (COX) Inhibition

The foundational mechanism of Pelubiprofen, like all NSAIDs, is the inhibition of cyclooxygenase enzymes, which are critical for the synthesis of pro-inflammatory mediators.

• Role of COX Enzymes: The COX enzymes, COX-1 and COX-2, catalyze the conversion of arachidonic acid into prostaglandin H2 (PGH2​), the precursor to various prostaglandins, thromboxanes, and prostacyclins.[12] These eicosanoids are key mediators of inflammation, pain, and fever. The constitutive isoform, COX-1, is present in most tissues and is responsible for producing prostaglandins that have homeostatic functions, such as protecting the gastric mucosa and supporting platelet aggregation and renal blood flow.[12] In contrast, the COX-2 isoform is typically expressed at low levels but is strongly induced at sites of inflammation by cytokines and other inflammatory stimuli, where it produces the prostaglandins that drive the inflammatory response.[12]
• Pelubiprofen's COX Inhibition Profile: Pelubiprofen inhibits both COX-1 and COX-2 enzymes.[23] However, it does not do so with equal potency. In vitro enzymatic assays have quantified its inhibitory activity, revealing half-maximal inhibitory concentrations ( IC50​) of 10.66±0.99 µM for COX-1 and 2.88±1.01 µM for COX-2.[3]
• COX-2 Preference: The ratio of these IC50​ values (COX-1/COX-2) is approximately 3.7, which classifies Pelubiprofen as a moderately COX-2 preferential inhibitor.[4] This means that at therapeutic concentrations, it is more potent at inhibiting the pro-inflammatory COX-2 enzyme than the homeostatic COX-1 enzyme. However, this preference is modest and distinct from that of highly selective COX-2 inhibitors (coxibs), which often have selectivity ratios of over 100.
• Pharmacodynamic Consequences: The direct consequence of COX inhibition is a potent reduction in the production of prostaglandin E2 (PGE2​), a key mediator of pain sensitization, vasodilation, and fever.[3] This reduction in PGE2​ synthesis is the direct molecular basis for Pelubiprofen's analgesic, anti-inflammatory, and antipyretic effects.[20]

3.2 Secondary Mechanism of Action: NF-κB Pathway Modulation

Beyond direct enzyme inhibition, Pelubiprofen possesses a second, distinct anti-inflammatory mechanism involving the suppression of a critical intracellular signaling pathway.

• The NF-κB Signaling Pathway: The Nuclear Factor-kappa B (NF-κB) family of transcription factors serves as a master regulator of the inflammatory response. In its inactive state, NF-κB is held in the cytoplasm by an inhibitory protein, IκB-α. Upon stimulation by inflammatory signals (such as lipopolysaccharide or pro-inflammatory cytokines), a cascade of upstream kinases is activated, leading to the phosphorylation and subsequent degradation of IκB-α. This releases NF-κB, allowing it to translocate to the nucleus, where it binds to DNA and initiates the transcription of a wide array of pro-inflammatory genes, including COX-2, inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6).[3]
• Pelubiprofen's Effect on the Pathway: Preclinical studies have demonstrated that Pelubiprofen significantly attenuates the activation of the NF-κB pathway.[3] It achieves this by targeting key upstream kinases in the signaling cascade. Specifically, Pelubiprofen inhibits the phosphorylation of Transforming growth factor-β Activated Kinase-1 (TAK1) and IκB Kinase-β (IKK-β).[3]
• Downstream Consequences: By inhibiting TAK1 and IKK-β, Pelubiprofen prevents the phosphorylation and degradation of IκB-α. This action effectively "locks" NF-κB in the cytoplasm, preventing its nuclear translocation and blocking its ability to drive the expression of inflammatory genes.[3]

3.3 Integrated Pharmacodynamic Profile

The combination of these two mechanisms results in a powerful and comprehensive anti-inflammatory effect. Pelubiprofen simultaneously blocks the activity of existing COX enzymes and suppresses the synthesis of new COX-2 enzymes and other key inflammatory proteins.[3] This dual action provides a robust molecular basis for the significant anti-inflammatory, analgesic, and antipyretic properties observed in both preclinical models and clinical trials.[3] The antipyretic effect, for example, was clinically confirmed in a Phase III trial where Pelubiprofen was shown to be non-inferior to loxoprofen in reducing fever in patients with URTIs.[9]

This dual mechanism, however, creates a notable therapeutic paradox. The development of COX-2 preferential drugs was historically driven by the goal of improving GI safety by sparing COX-1. Pelubiprofen's pharmacology reveals a more complex picture. Its moderate COX-2 preference means it retains significant COX-1 inhibitory activity, which is the primary cause of NSAID-induced gastropathy. At the same time, its potent secondary anti-inflammatory mechanism via NF-κB inhibition enhances its overall efficacy, positioning it closer to a powerful traditional NSAID. This explains the seemingly contradictory findings in clinical trials: while effective, its GI safety profile was found to be inferior to the highly selective COX-2 inhibitor celecoxib, a direct consequence of its residual COX-1 activity.[4] Therefore, Pelubiprofen occupies a challenging therapeutic space where its enhanced efficacy mechanism is coupled with a safety profile that does not fully align with the GI-sparing rationale of a true coxib.

4.0 Pharmacokinetics and Metabolism (ADME)

The disposition of Pelubiprofen in the body—its absorption, distribution, metabolism, and excretion (ADME)—is characterized by its nature as a prodrug that is rapidly converted to its major active metabolite. These pharmacokinetic properties are essential for understanding its clinical efficacy, dosing regimen, and potential for drug interactions.

4.1 Absorption

Pelubiprofen is designed for oral administration and undergoes rapid absorption from the gastrointestinal tract.[20]

• Route and Rate of Absorption: Following oral intake, the drug is absorbed quickly, with studies of immediate-release formulations reporting a time to maximum plasma concentration (Tmax​) of approximately 0.33 to 0.50 hours.[11] This rapid absorption facilitates a prompt onset of analgesic action, which is beneficial for acute pain conditions.[22]
• Prodrug Characteristics: Pelubiprofen is classified as a prodrug of 2-arylpropionic acid.[4] This designation is central to its pharmacokinetic profile. While the parent molecule has intrinsic activity, it is rapidly and extensively metabolized to its active form after absorption. The parent drug's extremely short half-life (less than 30 minutes) means it functions primarily as a delivery system for its more stable and pharmacologically active metabolite.[28] Consequently, the sustained therapeutic effect observed clinically is mediated almost entirely by this metabolite, not the transient parent compound. Any comprehensive analysis of Pelubiprofen's pharmacodynamics or interaction potential must therefore focus on the properties of its active metabolite.
• Impact of Formulation: As noted previously, the low aqueous solubility of the parent molecule prompted the development of a tromethamine salt formulation. A comparative pharmacokinetic study demonstrated that pelubiprofen tromethamine exhibits improved absorption, achieving a higher maximum plasma concentration (Cmax​) and greater overall exposure (Area Under the Curve, AUC) compared to the standard pelubiprofen formulation.[11] This indicates that the salt formulation successfully overcomes some of the dissolution-related absorption limitations of the parent drug. A Phase I trial (NCT01870102) was also initiated to formally assess the effect of food on the absorption of a sustained-release formulation, though specific outcomes were not available.[30]

4.2 Distribution

Once absorbed into the systemic circulation, Pelubiprofen and its metabolites are widely distributed.

• Plasma Protein Binding: A key characteristic of Pelubiprofen is its high affinity for plasma proteins. Both the parent drug and its metabolites are extensively bound, with reported binding percentages ranging from 93.3% to 98.9%.[23] This high degree of protein binding means that only a small fraction of the drug is free in the plasma to exert its pharmacological effect. This property also represents a significant, albeit latent, risk factor for drug-drug interactions. Co-administration with other highly protein-bound drugs (e.g., warfarin, sulfonylureas) could lead to competitive displacement from binding sites. Such displacement would increase the free concentration of either Pelubiprofen or the co-administered drug, potentially leading to enhanced effects or toxicity without any change in the total plasma concentration.
• Tissue Distribution: The drug is reported to distribute rapidly into tissues, with notable concentrations found in the liver and kidneys, the primary organs of metabolism and excretion, respectively.[23]

4.3 Metabolism

Pelubiprofen undergoes extensive and rapid hepatic metabolism, which is the defining feature of its pharmacokinetic profile.

• Site and Enzymes: Metabolism occurs primarily in the liver and is mediated by cytochrome P450 (CYP450) enzymes.[22] A key metabolic transformation is the reduction of the α,β-unsaturated ketone moiety, a reaction catalyzed by the enzyme Leukotriene B4 12-hydroxydehydrogenase/15-ketoprostaglandin Delta 13-reductase (LTB4 12-HD/PGR).[16]
• Major Active Metabolite: The metabolic process rapidly converts Pelubiprofen into its major and predominant active metabolite, trans-alcohol pelubiprofen.[28] This metabolite is pharmacologically active and, due to the short half-life of the parent drug, is responsible for the majority of the sustained therapeutic effect. Another minor active metabolite, unsaturated-alcohol pelubiprofen, has also been identified.[28] The importance of the trans-alcohol metabolite is underscored by the fact that dedicated pharmacokinetic studies routinely measure its plasma concentrations alongside the parent drug to fully characterize drug exposure.[28]

4.4 Excretion

The elimination of Pelubiprofen and its metabolites from the body occurs primarily through the kidneys.

• Route of Excretion: The primary route of elimination is renal, with metabolites being excreted in the urine.[22]
• Half-Life: The parent drug, Pelubiprofen, has a remarkably short mean elimination half-life, estimated to be between 0.37 and 0.41 hours.[28] This reflects its rapid conversion to metabolites. The overall duration of action is therefore dependent on the half-life of its active metabolites.
• Renal Clearance: A substantial fraction of the administered dose, approximately 26.3%, is ultimately excreted via the urine.[28] This significant reliance on renal clearance means that caution is warranted when administering the drug to patients with impaired kidney function.
• Accumulation: Studies involving repeated administration (e.g., 60 mg three times daily for seven days) have shown no evidence of accumulation of either Pelubiprofen or its metabolites in the plasma, indicating that the elimination pathways are efficient and not saturated at therapeutic doses.[23]

5.0 Clinical Evidence and Therapeutic Applications

The clinical utility of Pelubiprofen has been established through a series of Phase III and IV clinical trials, leading to its approval for several common inflammatory conditions and ongoing investigation for others. This section critically evaluates the evidence supporting its use and analyzes its efficacy in comparison to other established NSAIDs.

5.1 Approved and Investigational Indications

Pelubiprofen has secured regulatory approval in several countries for core rheumatological and musculoskeletal indications, while its clinical development program continues to explore its utility in other areas of pain and inflammation.

• Approved Indications in South Korea:
• Osteoarthritis: Approved in 2007 for the relief of signs and symptoms.[4]
• Low Back Pain: Indication expanded in 2010 for symptomatic relief.[4]
• Rheumatoid Arthritis: Approved in 2012 for the relief of signs and symptoms.[4]
• Investigational and Phase III Indications: Pelubiprofen has been studied in late-stage clinical trials for a number of other conditions, reflecting an active life-cycle management strategy:
• Acute Upper Respiratory Tract Infection (URTI) / Fever: A Phase III trial (NCT01779271) has been completed, evaluating its antipyretic efficacy.[5]
• Post-traumatic Acute Pain: A Phase III trial (NCT03874247) has been conducted to assess its analgesic effect in acute traumatic injury.[5]
• Primary Dysmenorrhea: The drug has reached Phase III development for this indication.[5]

5.2 Analysis of Pivotal Clinical Trials

The clinical evidence base for Pelubiprofen rests on several key non-inferiority trials that benchmarked its performance against other widely used anti-inflammatory agents. A summary of these pivotal studies is presented in Table 2.

Table 2: Summary of Key Phase III/IV Clinical Trials for Pelubiprofen

ClinicalTrials.gov ID	Indication	Comparator	Design	Key Findings	Source Snippet(s)
NCT01781702	Rheumatoid Arthritis	Celecoxib (200 mg)	6-week, multicenter, randomized, double-blind, non-inferiority	Pelubiprofen was non-inferior to celecoxib for pain reduction (VAS) and stiffness relief. However, Pelubiprofen was associated with a higher frequency of adverse drug reactions, particularly gastrointestinal events.	4
NCT01779271	Acute Upper Respiratory Tract Infection (Fever)	Loxoprofen (60 mg)	Multicenter, randomized, double-blind, non-inferiority	A single 30 mg dose of Pelubiprofen was non-inferior to loxoprofen in reducing axillary temperature at 4 hours post-dose, with no significant differences in safety.	6
Not specified (Phase IV)	Symptomatic Knee Osteoarthritis	Aceclofenac (200 mg)	4-week, double-blind, randomized, multicenter, non-inferiority	Pelubiprofen CR (90 mg/day) was non-inferior to aceclofenac for pain reduction (VAS). The Pelubiprofen CR group had a significantly lower incidence of adverse events, including GI AEs.	8
NCT03874247	Acute Traumatic Injury	Placebo	Randomized, double-blind, placebo-controlled, parallel, multi-center	Designed to evaluate the efficacy and safety of Pelubiprofen CR (45 mg) in acute traumatic pain. The trial is listed as completed, but results are not detailed in the available information.	7

5.3 Comparative Efficacy Analysis

The choice of comparators in these clinical trials reveals a deliberate and sophisticated market positioning strategy. Rather than competing directly against ubiquitous generic NSAIDs like ibuprofen or naproxen, the development program focused on benchmarking Pelubiprofen against both a highly selective COX-2 inhibitor (celecoxib) and a moderately selective NSAID (aceclofenac). This approach appears designed to carve out a specific therapeutic niche by demonstrating that Pelubiprofen is "as effective as a coxib" while being potentially "safer than other potent NSAIDs."

• vs. Celecoxib: In patients with rheumatoid arthritis, Pelubiprofen demonstrated comparable analgesic and anti-stiffness efficacy to celecoxib. The non-inferiority endpoint for pain reduction on a visual analog scale (VAS) was met.[4] This finding establishes its potency as equivalent to a leading selective COX-2 inhibitor in a challenging inflammatory condition. However, this efficacy came at the cost of a less favorable GI safety profile.
• vs. Aceclofenac: In a trial involving patients with symptomatic knee osteoarthritis, the controlled-release (CR) formulation of Pelubiprofen proved to be non-inferior to aceclofenac in terms of pain relief.[8] Significantly, in this study, the Pelubiprofen CR formulation was associated with a statistically significant lower incidence of adverse events, including GI-related side effects. This result is particularly important as it suggests that formulation technology may be a critical factor in mitigating the GI risks of Pelubiprofen.
• vs. Loxoprofen: For the treatment of fever associated with URTIs, a single dose of Pelubiprofen was shown to be as effective as loxoprofen, confirming its antipyretic activity in a clinical setting.[6]
• vs. Ibuprofen/Naproxen: Direct, head-to-head comparative clinical trial data for Pelubiprofen against ibuprofen or naproxen are not available in the provided documentation.[26] Although Pelubiprofen shares a structural heritage with ibuprofen, its clinical development has strategically avoided direct comparisons, focusing instead on the aforementioned comparators.

The contradictory safety outcomes observed in the celecoxib trial (worse GI safety for Pelubiprofen) versus the aceclofenac trial (better safety for Pelubiprofen CR) are highly significant. The most plausible explanation for this discrepancy lies in the different formulations used. The trial against celecoxib likely used an immediate-release (IR) formulation, which can create high local drug concentrations in the stomach, exacerbating GI irritation. In contrast, the controlled-release formulation used in the aceclofenac trial is designed to slow the rate of drug dissolution, thereby reducing local irritation and improving GI tolerability. This strongly suggests that the formulation of Pelubiprofen is a critical determinant of its clinical safety profile, and the CR version may represent a significant therapeutic advancement over the original IR tablet.

6.0 Safety and Tolerability Profile

The safety profile of Pelubiprofen is consistent with that of other nonsteroidal anti-inflammatory drugs, encompassing risks related to the gastrointestinal, cardiovascular, and renal systems. However, drug-specific data from clinical trials provide a more nuanced understanding of its relative tolerability.

6.1 Common and Serious Adverse Drug Reactions (ADRs)

• Gastrointestinal (GI) Effects: GI disturbances are among the most frequently reported adverse effects. Common symptoms include dyspepsia (indigestion), nausea, vomiting, abdominal pain, diarrhea, and constipation.[4]
• Serious GI Risk: In line with all NSAIDs, Pelubiprofen carries a risk of serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These events can be fatal, may occur at any time during treatment, and can manifest without prior warning symptoms.[35] The risk is notably elevated in elderly patients and those with a history of peptic ulcer disease or GI bleeding.[35]
• Comparative GI Risk: The clinical trial data for Pelubiprofen present a complex picture of its GI safety. A head-to-head study in rheumatoid arthritis patients found that the frequency of GI ADRs was significantly higher with Pelubiprofen (20.8%) compared to the highly selective COX-2 inhibitor celecoxib (8.8%).[4] This outcome underscores a significant disconnect between the theoretical safety advantages of a prodrug with moderate COX-2 preference and the observed clinical reality. The initial hypothesis that these features would confer superior GI safety was not supported when compared to a highly selective agent. Conversely, a study in osteoarthritis patients comparing the controlled-release (CR) formulation of Pelubiprofen to aceclofenac found that the Pelubiprofen CR group had a statistically significant lower rate of GI adverse events (3% vs. 11%).[10] This suggests that formulation plays a crucial role in determining the drug's GI tolerability.
• Cardiovascular (CV) Events:
• Serious CV Risk: Pelubiprofen is subject to the class-wide warning for NSAIDs regarding an increased risk of serious and potentially fatal cardiovascular thrombotic events, such as myocardial infarction and stroke.[35] This risk may appear early in treatment and can increase with the duration of use, particularly in patients with existing cardiovascular disease or risk factors.[35]
• Renal Effects:
• NSAID use, including Pelubiprofen, is associated with a risk of renal toxicity, which can manifest as renal papillary necrosis, fluid retention, and edema.[35] Caution is required when prescribing for patients with pre-existing renal impairment, heart failure, dehydration, or hypovolemia.[35]
• Hepatic Effects:
• Borderline elevations of liver enzymes may occur. Although rare, severe hepatic reactions, including jaundice, fatal fulminant hepatitis, and liver failure, have been reported with the NSAID class.[35] Patients should be monitored for signs of liver dysfunction.
• Hypertension: Pelubiprofen can induce new-onset hypertension or exacerbate pre-existing hypertension, which can contribute to the overall cardiovascular risk.[35] Blood pressure should be monitored closely during therapy.
• Dermatologic Reactions:
• Rare but severe and potentially fatal skin reactions have been associated with NSAIDs. These include exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN), which can occur without warning.[35]
• Other Reported ADRs: Other adverse effects noted in clinical trials and post-marketing surveillance include dizziness, drowsiness, headache, and edema.[4]

6.2 Contraindications

The use of Pelubiprofen is contraindicated in several specific patient populations and clinical scenarios to mitigate the risk of serious adverse events:

• Patients with a known hypersensitivity to Pelubiprofen, or those who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.[36]
• Patients with active peptic ulcer disease.[36]
• For the treatment of peri-operative pain in the context of coronary artery bypass graft (CABG) surgery.[35]
• Patients with severe hepatic dysfunction, severe renal dysfunction, or severe heart failure.[36]
• Patients with severe, uncontrolled hypertension.[36]
• Patients with severe hematological abnormalities.[36]
• During lactation.[36]

6.3 Use in Special Populations

• Pregnancy: As with other NSAIDs, Pelubiprofen should be avoided during pregnancy, especially in the third trimester, due to the risk of inhibiting prostaglandin synthesis, which can lead to premature closure of the fetal ductus arteriosus.[35]
• Elderly Patients: Caution is advised in the geriatric population, as these patients are at a higher risk for serious GI, cardiovascular, and renal adverse events from NSAIDs. Dose adjustments may be necessary.[35]
• Renal and Hepatic Impairment: Given that Pelubiprofen is metabolized by the liver and its metabolites are excreted by the kidneys, its use should be approached with caution in patients with hepatic or renal impairment.[22]

7.0 Drug-Drug Interactions

Specific drug-drug interaction studies for Pelubiprofen are limited in the available literature. Therefore, a significant portion of the interaction profile must be inferred from the well-established class effects of nonsteroidal anti-inflammatory drugs.

7.1 Pharmacodynamic Interactions

These interactions involve additive or opposing effects on physiological systems, primarily related to hemostasis and blood pressure regulation.

• Anticoagulants and Antiplatelet Agents: Co-administration of Pelubiprofen with anticoagulants (e.g., warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel) is expected to significantly increase the risk of bleeding.[36] This is due to a dual effect: NSAIDs can cause GI mucosal injury, creating a potential bleeding site, and they also inhibit platelet function by blocking thromboxane A2 synthesis via COX-1.
• Other NSAIDs: The concurrent use of Pelubiprofen with other systemic NSAIDs, including aspirin (>325 mg/day) and selective COX-2 inhibitors, should be avoided. This combination increases the risk of additive gastrointestinal toxicity (e.g., ulceration, bleeding) without providing any proven synergistic analgesic or anti-inflammatory benefit.[36]
• Corticosteroids: The concomitant use of oral corticosteroids and NSAIDs is known to potentiate the risk of serious gastrointestinal ulceration and bleeding.[40]

7.2 Pharmacokinetic Interactions

These interactions involve the alteration of the absorption, distribution, metabolism, or excretion of Pelubiprofen or co-administered drugs.

• Antihypertensives and Diuretics: NSAIDs can diminish the therapeutic effects of many antihypertensive medications, including ACE inhibitors, angiotensin II receptor blockers (ARBs), and beta-blockers. They can also reduce the natriuretic effect of loop and thiazide diuretics.[36] The underlying mechanism is the inhibition of renal prostaglandin synthesis, which plays a role in regulating renal blood flow and sodium excretion. This interaction can lead to worsened blood pressure control and an increased risk of acute renal impairment, particularly in elderly or volume-depleted patients.[36]
• Methotrexate: Concurrent use with methotrexate can be hazardous. NSAIDs can reduce the renal clearance of methotrexate, leading to elevated plasma concentrations and a significantly increased risk of methotrexate-related toxicity, including myelosuppression and mucositis.[36]
• Lithium: NSAIDs are known to decrease the renal excretion of lithium, resulting in elevated plasma lithium levels and an increased risk of lithium toxicity. Close monitoring of lithium levels is essential if co-administration is necessary.[36]
• Highly Protein-Bound Drugs: As established by its pharmacokinetic profile, Pelubiprofen is highly bound to plasma proteins.[23] This creates a theoretical potential for displacement interactions with other highly bound drugs. While specific studies are lacking, caution is warranted when co-prescribing with agents like warfarin or sulfonylureas, as displacement could increase the free fraction and pharmacological activity of either drug.

7.3 Specific Interaction Study

While comprehensive interaction data is sparse, one dedicated clinical study has been conducted to assess a specific drug combination.

• Pelubiprofen and Eperisone: A pharmacokinetic study in healthy volunteers evaluated the co-administration of sustained-release Pelubiprofen (45 mg) and the centrally acting muscle relaxant eperisone hydrochloride (75 mg). The results showed no clinically significant pharmacokinetic interactions. The systemic exposure (Cmax​ and AUC) of Pelubiprofen, its major active metabolite (trans-alcohol pelubiprofen), and eperisone were not meaningfully altered when the drugs were given together compared to when they were administered alone.[28] This finding provides specific evidence supporting the safe concurrent use of this particular combination, which is clinically relevant for treating musculoskeletal conditions involving both pain and muscle spasm.

8.0 Dosage, Administration, and Commercial Information

This section provides practical guidance on the clinical use of Pelubiprofen, including recommended dosing, available formulations, and its commercial and regulatory status.

8.1 Dosing Regimens by Indication

The recommended dosage of Pelubiprofen varies depending on the specific formulation (immediate-release vs. controlled-release) and the clinical indication. The approved dosing regimens are summarized in Table 3.

Table 3: Recommended Dosing of Pelubiprofen by Indication and Formulation

Indication	Formulation	Dosage	Source Snippet(s)
Osteoarthritis, Low Back Pain	Immediate-Release (IR) Tablet	30 mg, three times daily	23
Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Pain	Controlled-Release (CR) Tablet	45 mg, twice daily	32
Rheumatoid Arthritis	Immediate-Release (IR) Tablet	30 mg, three times daily	23
Maximum Daily Dose (IR)	Immediate-Release (IR) Tablet	90 mg (3 tablets)	23

It is recommended that Pelubiprofen be administered after meals to potentially reduce gastrointestinal irritation.[7] As with all NSAIDs, the guiding principle for administration is to use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.[35]

8.2 Available Formulations

Daewon Pharmaceutical has developed several formulations of Pelubiprofen to improve its clinical utility, dosing convenience, and tolerability.

• Pelubi® Tab (Immediate-Release): This is the standard formulation, available as 30 mg tablets intended for administration three times daily.[23]
• Pelubi® SR/CR Tab (Sustained/Controlled-Release): A 45 mg sustained- or controlled-release tablet was developed to offer a more convenient twice-daily dosing schedule. This formulation utilizes technology that forms microchannels to control the rate of drug release, which may also contribute to minimizing local GI irritation and improving the overall side effect profile.[2]
• Pelubiprofen Tromethamine: This is a salt formulation developed to address the parent drug's poor aqueous solubility. By improving solubility, this formulation aims to enhance the rate and extent of absorption, leading to a more reliable pharmacokinetic profile.[1]

8.3 Global Regulatory Status, Manufacturers, and Brand Names

• Originator/Developer: Pelubiprofen was developed by Daewon Pharmaceutical Co., Ltd., a South Korean company. It was the 12th new molecular entity to be approved by the Korean Ministry of Food and Drug Safety (MFDS).[1]
• Brand Names: The primary global brand name for Pelubiprofen is Pelubi®.[1]
• Approved Countries: Pelubiprofen was first approved in South Korea in 2007.[5] It is also marketed in Russia and is undergoing regulatory expansion into other markets, including a recent deal for export to Indonesia.[1]
• Manufacturers and Suppliers: While Daewon Pharmaceutical is the originator, various other companies are involved in the supply chain, either as licensees or as manufacturers of the active pharmaceutical ingredient (API). These include Akrikhin, which markets the drug in Russia, and several API manufacturers based in South Korea (e.g., Enzychem, Kyungbo) and China (e.g., Hunan Jiudian HONGYANG Pharmaceutical).[5] Other chemical suppliers like Simson Pharma and Venkatasai Life Sciences also list the compound.[48]

9.0 Expert Synthesis and Concluding Remarks

This final section provides an integrated assessment of Pelubiprofen, synthesizing the pharmacological, pharmacokinetic, and clinical data to define its overall therapeutic profile and its position within the crowded landscape of anti-inflammatory drugs.

9.1 Integrated Benefit-Risk Assessment

• Benefits: Pelubiprofen is a potent nonsteroidal anti-inflammatory drug whose efficacy has been rigorously established in non-inferiority trials against well-regarded comparators like celecoxib and aceclofenac. Its clinical utility is proven for managing chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis, as well as for acute pain and fever. A key differentiating feature is its dual mechanism of action—combining direct COX inhibition with suppression of the NF-κB inflammatory signaling pathway—which may contribute to its robust anti-inflammatory effects. Furthermore, the successful development of a controlled-release (CR) formulation represents a significant therapeutic advancement, offering the dual advantages of a more convenient twice-daily dosing regimen and, critically, an improved gastrointestinal safety profile compared to some other NSAIDs.
• Risks: The risks associated with Pelubiprofen are substantial and largely align with those of the NSAID class. It carries the standard warnings for potentially fatal cardiovascular thrombotic events and serious renal toxicity. Its gastrointestinal safety profile is particularly complex. Despite being designed as a prodrug with moderate COX-2 preference to improve GI tolerability, the immediate-release formulation demonstrated a higher incidence of GI adverse events than the highly selective COX-2 inhibitor celecoxib. This indicates that its residual COX-1 inhibition is clinically significant and that it cannot be considered a "GI-sparing" agent in the same vein as the coxib class. While the CR formulation showed superior GI safety compared to aceclofenac, the overall GI risk remains a primary consideration in patient selection.
• Overall Assessment: Pelubiprofen is a valuable and effective option in the armamentarium for managing pain and inflammation. Its CR formulation, in particular, appears to offer a favorable balance of efficacy, convenience, and improved tolerability. However, it is not a universally superior NSAID. Its place in therapy is for patients who require potent anti-inflammatory action and for whom the specific clinical evidence is most compelling (e.g., in osteoarthritis where the CR formulation was shown to be safer than aceclofenac). The decision to prescribe Pelubiprofen must be individualized, with a thorough assessment of the patient's baseline gastrointestinal and cardiovascular risk factors being paramount.

9.2 Unanswered Questions and Future Research Directions

Despite its established efficacy, several key questions remain that, if answered, could further clarify Pelubiprofen's optimal role in clinical practice.

• Direct Comparison to Standard NSAIDs: A significant gap in the clinical evidence is the lack of direct, head-to-head comparative trials against the most widely used traditional NSAIDs, such as ibuprofen and naproxen. Such studies would be invaluable for definitively positioning Pelubiprofen's relative efficacy and safety within the broader NSAID market.
• Long-Term Cardiovascular Safety: While Pelubiprofen carries the class warning for cardiovascular risk, dedicated long-term cardiovascular outcome trials (CVOTs), analogous to the PRECISION trial that compared celecoxib, ibuprofen, and naproxen, have not been conducted.[50] A specific CVOT for Pelubiprofen would be necessary to precisely quantify its cardiovascular risk profile relative to other agents.
• Clinical Relevance of NF-κB Inhibition: The clinical significance of Pelubiprofen's secondary mechanism—inhibition of the NF-κB pathway—remains to be fully elucidated. Future research should investigate whether this unique action translates into tangible clinical benefits beyond standard anti-inflammatory effects, such as a potential for disease modification in chronic arthritic conditions.
• Enantiomer-Specific Pharmacology: Pelubiprofen is marketed as a racemic mixture. A fundamental area for future research would be to characterize the distinct pharmacokinetic and pharmacodynamic properties of the individual R- and S-enantiomers. This could pave the way for a "chiral switch" to a single-enantiomer product, which could potentially offer an improved therapeutic index with greater efficacy, lower toxicity, or both.
• Role in Multimodal Analgesia: The development of combination products, such as the fixed-dose combination of Pelubiprofen and tramadol (DW-1021), is a promising avenue.[5] Further clinical trials are needed to define the efficacy and safety of such combinations and their role in multi-modal approaches to pain management, which aim to improve analgesia while minimizing opioid consumption.

Works cited

1. Pelubiprofen - Wikipedia, accessed September 22, 2025, https://en.wikipedia.org/wiki/Pelubiprofen
2. Pelubi Tab is Daewon Pharm's first new treatment and the 12th new medicine of Korea, approved by KFDA. Daewon Pharm developed this new medicine, containing pelubiprofen which belongs to the non-steroidal anti-inflammatory drugs (NSAIDs), with R&D from new materials to production. Compared to existing products, Pelubi Tab has excellent effects as an anti-inflammatory and analgesic drug, and has less side effects related to gastrointestinal tract. Initially, Pelubi Tab was known to be efficacious to treat or relieve the symptoms of degenerative joint disease, but the relief of backache and efficacy for rheumatoid arthritis and fever have been also added as the result of continuous clinical development. Incrementally modifying this product, Daewon Pharms has recently presented Pelubi SR Tab, which enables sustained release by forming microchannel. This feature minimizes side effects on gastrointestinal tract, and contributed on convenience of less frequent dosing as twice a day., accessed September 22, 2025, https://www.daewonpharm.com/eng/rnd/sub05_01.jsp?mb=03&mm=35&ms=351&lang=1
3. Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-κB inactivation - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/21809372/
4. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial - PubMed Central, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4247700/
5. Pelubiprofen - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 22, 2025, https://synapse.patsnap.com/drug/9ba6eca0bf3b46a59e7e7f65afa864dd
6. (PDF) The Efficacy and Safety of Pelubiprofen in the Treatment of Acute Upper Respiratory Tract Infection: A Multicenter, Randomized, Double-Blind, Non-Inferiority Phase III Clinical Trial Compared to Loxoprofen - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/publication/389247236_The_Efficacy_and_Safety_of_Pelubiprofen_in_the_Treatment_of_Acute_Upper_Respiratory_Tract_Infection_A_Multicenter_Randomized_Double-Blind_Non-Inferiority_Phase_III_Clinical_Trial_Compared_to_Loxoprofe
7. Study Details | NCT03874247 | Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury, accessed September 22, 2025, https://clinicaltrials.gov/study/NCT03874247
8. Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis: A double-blinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, non-inferiority clinical trial - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/32991606/
9. The Efficacy and Safety of Pelubiprofen in the Treatment of Acute Upper Respiratory Tract Infection: A Multicenter, Randomized, Double-Blind, Non-Inferiority Phase III Clinical Trial Compared to Loxoprofen - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11901028/
10. (PDF) Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis: A double-blinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, non-inferiority clinical trial - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/publication/345968877_Efficacy_and_safety_of_short-term_use_of_a_pelubiprofen_CR_and_aceclofenac_in_patients_with_symptomatic_knee_osteoarthritis_A_double-blinded_randomized_multicenter_active_drug_comparative_parallel-gro
11. The pharmacokinetic parameters of different formulations of pelubiprofen. - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/figure/The-pharmacokinetic-parameters-of-different-formulations-of-pelubiprofen_tbl2_370136538
12. Pelubiprofen: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 22, 2025, https://go.drugbank.com/drugs/DB12150
13. Pelubiprofen | C16H18O3 - ChemSpider, accessed September 22, 2025, https://www.chemspider.com/Chemical-Structure.4445391.html
14. pelubiprofen | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=9876
15. Pelubiprofen | C16H18O3 | CID 5282203 - PubChem, accessed September 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Pelubiprofen
16. Pelubiprofen | CS-670 | DW-330 | RS-2131 | CAS#69956-77-0 - MedKoo Biosciences, accessed September 22, 2025, https://www.medkoo.com/products/10856
17. pelubiprofen | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=immuno&ligandId=9876
18. pelubiprofen | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=9876
19. Compound: PELUBIPROFEN (CHEMBL69308) - ChEMBL - EMBL-EBI, accessed September 22, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL69308
20. Pelubiprofen | COX-2 Inhibitor - TargetMol, accessed September 22, 2025, https://www.targetmol.com/compound/pelubiprofen
21. Pelubiprofen | prodrug of 2-arylpropionic acid | CAS# 69956-77-0 | InvivoChem, accessed September 22, 2025, https://www.invivochem.com/pelubiprofen.html
22. What is the mechanism of Pelubiprofen? - Patsnap Synapse, accessed September 22, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-pelubiprofen
23. Pelubio - PharmArtis, accessed September 22, 2025, https://pharmartis.com/products/pelubio/?lang_ui=en
24. Pelubiprofen | COX Inhibitor - MedchemExpress.com, accessed September 22, 2025, https://www.medchemexpress.com/pelubiprofen.html
25. CAS 69956-77-0 Pelubiprofen - BOC Sciences, accessed September 22, 2025, https://www.bocsci.com/product/pelubiprofen-cas-69956-77-0-325712.html
26. A new representative of the group of non-steroidal anti-inflammatory drugs in the therapeutic arsenal of a Russian doctor: pelubiprofen | Karateev | Neurology, Neuropsychiatry, Psychosomatics, accessed September 22, 2025, https://nnp.ima-press.net/nnp/article/view/2455
27. The Efficacy and Safety of Pelubiprofen in the Treatment of Acute Upper Respiratory Tract Infection: A Multicenter, Randomized, Double-Blind, Non-Inferiority Phase III Clinical Trial Compared to Loxoprofen - MDPI, accessed September 22, 2025, https://www.mdpi.com/2077-0383/14/5/1450
28. Pharmacokinetic Interactions Between Pelubiprofen and Eperisone Hydrochloride: A Randomized, Open-label, Crossover Study of Healthy Korean Men - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/27989618/
29. Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects - MDPI, accessed September 22, 2025, https://www.mdpi.com/1999-4923/15/4/1280
30. NCT01870102 | Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects | ClinicalTrials.gov, accessed September 22, 2025, https://clinicaltrials.gov/study/NCT01870102
31. Development and validation of an LC-MS/MS method for the, accessed September 22, 2025, https://www.researchgate.net/publication/271274412_Development_and_validation_of_an_LC-MSMS_method_for_the_determination_of_pelubiprofen_and_its_active_metabolite_trans-alcohol_in_human_plasma_and_its_application_to_pharmacokinetic_study
32. Daewon Pharm, accessed September 22, 2025, https://www.daewonpharm.com/eng/products/sub03_01_view.jsp?mb=02&mm=23&ms=231&lang=1&PRD_NO=97
33. A new representative of the group of non-steroidal anti-inflammatory drugs in the therapeutic arsenal of a Russian doctor: pelubiprofen - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/publication/389065171_A_new_representative_of_the_group_of_non-steroidal_anti-inflammatory_drugs_in_the_therapeutic_arsenal_of_a_Russian_doctor_pelubiprofen
34. What are the side effects of Pelubiprofen? - Patsnap Synapse, accessed September 22, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-pelubiprofen
35. Reference ID: 3928083 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018766s020lbl.pdf
36. [Table 1] Adverse events occurring in clinical trials (%), accessed September 22, 2025, https://www.daewonpharm.com/_inc/pdfen.jsp?idx=10
37. Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis - Research journals - PLOS, accessed September 22, 2025, https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0238024
38. Flurbiprofen: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 22, 2025, https://go.drugbank.com/drugs/DB00712
39. www.daewonpharm.com, accessed September 22, 2025, https://www.daewonpharm.com/_inc/pdfen.jsp?idx=10#:~:text=15)%20Skin%20Reactions%20%3A%20Pelubiprofen%20cause,patients%20without%20prior%20known%20allergy.%2520Skin%2520Reactions%2520%253A%2520Pelubiprofen%2520cause,patients%2520without%2520prior%2520known%2520allergy.&sa=D&source=editors&ust=1758544453017453&usg=AOvVaw2CciCcOS6F28yT09o7aWD2)
40. Flurbiprofen (oral route) - Side effects & dosage - Mayo Clinic, accessed September 22, 2025, https://www.mayoclinic.org/drugs-supplements/flurbiprofen-oral-route/description/drg-20069793
41. pelubiprofen | Actions and Spectrum - medtigo, accessed September 22, 2025, https://medtigo.com/drug/pelubiprofen/
42. Drug Interaction Report - flurbiprofen celecoxib, accessed September 22, 2025, https://www.drugs.com/interactions-check.php?drug_list=560-0,1121-0&professional=1
43. FlurbiPro Interactions Checker - Drugs.com, accessed September 22, 2025, https://www.drugs.com/drug-interactions/flurbiprofen,flurbipro.html
44. PRODUCT Pelubi Tab - Daewon Pharm, accessed September 22, 2025, https://www.daewonpharm.com/eng/products/sub03_01_view.jsp?mb=02&mm=23&ms=231&lang=1&PRD_NO=10
45. Pelubi (pelubiprofen) / Daewon Pharma - LARVOL DELTA, accessed September 22, 2025, https://delta.larvol.com/Products/?ProductId=e5ea47c1-e141-4ed3-831f-1a8617fd212e
46. Akrikhin produces an original non-steroidal anti-inflammatory drug, accessed September 22, 2025, https://www.akrikhin.com/about/news/4690/
47. Pelubiprofen - API Manufacturer List - Echemi, accessed September 22, 2025, https://www.echemi.com/drugs-ingredient-manufacturers/pd2204111009-pelubiprofen.html
48. Pelubiprofen | CAS No- 69956-77-0 | Simson Pharma Limited, accessed September 22, 2025, https://www.simsonpharma.com/product/pelubiprofen
49. Pelubiprofen | 69956-77-0 | : Venkatasai Life Sciences, accessed September 22, 2025, https://venkatasailifesciences.com/pelubiprofen--2
50. Prospective Randomized Evaluation of Celeboxib Integrated Safety Versus Ibuprofen or Naproxen - American College of Cardiology, accessed September 22, 2025, https://www.acc.org/latest-in-cardiology/clinical-trials/2016/11/12/00/01/precision
51. NCT01781702 | Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients | ClinicalTrials.gov, accessed September 22, 2025, https://clinicaltrials.gov/study/NCT01781702